You are here

Article Text

Article menu
Download PDFPDF
Editorial
Understanding the cost-effectiveness of bivalirudin

https://doi.org/10.1136/heartjnl-2012-301649

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests APA declares no competing interests. EM has received grant support from AstraZeneca, Eli Lilly, Daiichi Sankyo, Sanofi-Aventis and Bristol-Myers Squibb, and has received speaking honoraria/lecture fees from Sanofi-Aventis and Bristol-Myers Squibb. The opinions expressed in this article are not necessarily those of the editors or of the Heart Journal.

    • Provenance and peer review Commissioned; internally peer reviewed.